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Dear Editor, 
 
 The increasing worldwide incidence of inflammatory bowel diseases (IBD) steadily 
parallels the diffusion of Western life style [1]. Diet is considered the main factor associated 
to life style and induces significant alteration in the gut microbiome, the “ring chain” that can 
explain new onset of diseases, particularly inflammatory diseases [2–4]. 
Obesity also poses a major risk, not only for diet-related non communicable diseases, such as 
diabetes, but also for IBD [5]. Currently, bariatric surgery is the more appropriate therapeutic 
option for obese patients who failed an adequate exercise and diet program, and who present 
with obesity-related comorbid conditions. Few data about the efficacy and safety of bariatric 
surgery in patients affected by IBD are available in literature, probably due to the fear to 
perform abdominal surgery in these patients [6,7]. 
 In a recent interesting paper, McKenna et al. described the outcomes of 31 patients 
affected by IBD who underwent bariatric surgery, including Roux-en-Y gastric bypass 
(RYGB), sleeve gastrectomy (SG), and gastric band placement, at Mayo Clinic in Rochester, 
Minnesota [8]. They concluded that, in carefully selected IBD patients (in particular upon 
exclusion of Crohn’s disease patients with upper gastrointestinal active disease location), 
bariatric surgery seemed to be not only effective (weight lost at one and two years after 
surgery was of about 70% and 60%, respectively, comparable to the literature data [9]), but 
also safe (they did not observe any major surgical complication and no IBD patients 
relapsed). 
These results raise two issues. This study [8] supports the feasibility of bariatric 
surgery in patients with IBD, but a comparison with a control group of patients without IBD, 
matched for sex, age and comorbidities, who underwent bariatric surgery, would add more 
objective data regarding safety and efficacy of this type of intervention. Furthermore, a 
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comparison of two IBD groups, one that underwent bariatric surgery and a control non-
surgical group, would provide further information concerning the IBD evolution related to 
surgery. 
The second issue is a suggestion regarding the design of future studies on bariatric surgery in 
IBD patients. As reported above, microbiota, obesity and inflammation are believed to share a 
strong relationship. In our opinion, future studies should analyze gut microbiome of IBD 
patients before and after bariatric surgery and correlate differences with IBD course after this 
intervention. The question that remains is: could bariatric surgery, with its extraordinary 
effects on weight loss, be not only safe but also effective in reducing inflammation, through 
modification of gut microbiome? 
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